Advertisement

Molecular Medicine

, Volume 17, Issue 9–10, pp 1095–1106 | Cite as

Angiopoietin-1 Protects Heart against Ischemia/Reperfusion Injury through VE-Cadherin Dephosphorylation and Myocardiac Integrin-β1/ERK/Caspase-9 Phosphorylation Cascade

  • Sae-Won Lee
  • Joo-Yun Won
  • Hae-Young Lee
  • Ho-Jae Lee
  • Seock-Won Youn
  • Ji-Young Lee
  • Chung-Hyun Cho
  • Hyun-Jai Cho
  • Seil Oh
  • In-Ho Chae
  • Hyo-Soo Kim
Research Article

Abstract

Early reperfusion after myocardial ischemia that is essential for tissue salvage also causes myocardial and vascular injury. Cardioprotection during reperfusion therapy is an essential aspect of treating myocardial infarction. Angiopoietin-1 is an endothelialspecific angiogenic factor. The potential effects of angiopoietin-1 on cardiomyocytes and vascular cells undergoing reperfusion have not been investigated. We propose a protective mechanism whereby angiopoietin-1 increases the integrity of the endothelial lining and exerts a direct survival effect on cardiomyocytes under myocardial ischemia followed by reperfusion. First, we found that angiopoietin-1 prevents vascular leakage through regulating vascular endothelial (VE)-cadherin phosphorylation. The membrane expression of VE-cadherin was markedly decreased on hypoxia/reoxygenation but was restored by angiopoietin-1 treatment. Interestingly, these effects were mediated by the facilitated binding between SH2 domain-containing tyrosine phosphatase (SHP2) or receptor protein tyrosine phosphatase μ (PTPμ) and VE-cadherin, leading to dephosphorylation of VE-cadherin. siRNA against SHP2 or PTPμ abolished the effect of angiopoietin-1 on VE-cadherin dephosphorylation and thereby decreased levels of membrane-localized VE-cadherin. Second, we found that angiopoietin-1 prevented cardiomyocyte death, although cardiomyocytes lack the angiopoietin-1 receptor Tie2. Angiopoietin-1 increased cardiomyocyte survival through integrin-β1-mediated extracellular signal-regulated kinase (ERK) phosphorylation, which inhibited caspase-9 through phosphorylation at Thr125 and subsequently reduced active caspase-3. Neutralizing antibody against integrin-β1 blocked these protective effects. In a mouse myocardial ischemia/reperfusion model, angiopoietin-1 enhanced cardiac function and reduction in left ventricular-end systolic dimension (LV-ESD) and left ventricular-end diastolic dimension (LV-EDD) with an increase in ejection fraction (EF) and fractional shortening (FS). Our findings suggest the novel cardioprotective mechanisms of angiopoietin-1 that are achieved by reducing both vascular leakage and cardiomyocyte death after ischemia/reperfusion injury.

Notes

Acknowledgments

This study was supported by a grant for the Innovative Research Institute for Cell Therapy (A062260) and a National Research Foundation grant funded by the Korea government (Ministry of Education, Science and Technology [MEST]) (2010-0020257). H-S Kim is a professor of Molecular Medicine and Biopharmaceuticals Sciences, Seoul National University, and is sponsored by the World Class University program from the Ministry of Education and Science, Korea.

S-W Lee performed project planning, experimental design and data interpretation and prepared the manuscript. J-Y Won, H-Y Lee, J-Y Lee and S-W Youn performed cell culture and experiments and analyzed data. H-J Lee, C-H Cho, H-J Cho, S Oh and I-H Chae provided the mouse myocardial ischemia (MI) model and data analysis. H-S Kim provided project planning, data interpretation and funding and prepared the manuscript.

Supplementary material

10020_2011_1791095_MOESM1_ESM.pdf (988 kb)
Angiopoietin-1 Protects Heart against Ischemia/Reperfusion Injury through VE-Cadherin Dephosphorylation and Myocardiac Integrin-β1/ERK/Caspase-9 Phosphorylation Cascade

References

  1. 1.
    Bijnens B, Sutherland GR. (2008) Myocardial oedema: a forgotten entity essential to the understanding of regional function after ischaemia or reperfusion injury. Heart. 94:1117–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Kang HJ, Kim HS. (2008) G-CSF- and erythropoietin-based cell therapy is a promising strategy for angiomyogenesis in myocardial infarction. Expert Rev. Cardiovasc. Ther. 6:703–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Lefer AM, Tsao PS, Lefer DJ, Ma XL. (1991) Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J. 5:2029–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Fliss H, Gattinger D. (1996) Apoptosis in ischemic and reperfused rat myocardium. Circ. Res. 79:949–56.CrossRefPubMedGoogle Scholar
  5. 5.
    Prasad A, Stone GW, Holmes DR, Gersh B. (2009) Reperfusion injury, microvascular dysfunction, and cardioprotection: the “dark side” of reperfusion. Circulation. 120:2105–112.CrossRefPubMedGoogle Scholar
  6. 6.
    Lee SW, Kim WJ, Jun HO, Choi YK, Kim KW. (2009) Angiopoietin-1 reduces vascular endothelial growth factor-induced brain endothelial permeability via upregulation of ZO-2. Int. J. Mol. Med. 23:279–84.PubMedGoogle Scholar
  7. 7.
    Suri C, et al. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87:1171–80.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee SW, et al. (2003) SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat. Med. 9:900–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Yancopoulos GD, et al. (2000) Vascular-specific growth factors and blood vessel formation. Nature. 407:242–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Abdulmalek K, et al. (2001) Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. Am. J. Physiol. Lung Cell Mol. Physiol. 281:L582–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Takahashi K, et al. (2003) Adenoviral-delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction. Mol. Ther. 8:584–92.CrossRefPubMedGoogle Scholar
  12. 12.
    Carlson TR, Feng Y, Maisonpierre PC, Mrksich M, Morla AO. (2001) Direct cell adhesion to the angiopoietins mediated by integrins. J. Biol. Chem. 276:26516–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Dallabrida SM, Ismail N, Oberle JR, Himes BE, Rupnick MA. (2005) Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ. Res. 96:e8–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Cho CH, et al. (2005) Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ. Res. 97:86–94.CrossRefPubMedGoogle Scholar
  15. 15.
    Barone GW, Farley PC, Conerly JM, Flanagan TL, Kron IL. (1989) Morphological and functional techniques for assessing endothelial integrity: the use of Evans blue dye, silver stains, and endothelial derived relaxing factor. J. Card. Surg. 4:140–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Corada M, et al. (1999) Vascular endothelialcadherin is an important determinant of microvascular integrity in vivo. Proc. Natl. Acad. Sci. U. S. A. 96:9815–20.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Williamson CL, Dabkowski ER, Dillmann WH, Hollander JM. (2008) Mitochondria protection from hypoxia/reoxygenation injury with mitochondria heat shock protein 70 overexpression. Am. J. Physiol. Heart Circ. Physiol. 294:H249–56.CrossRefPubMedGoogle Scholar
  18. 18.
    Mestril R, Chi SH, Sayen MR, O’Reilly K, Dillmann WH. (1994) Expression of inducible stress protein 70 in rat heart myogenic cells confers protection against simulated ischemia-induced injury. J. Clin. Invest. 93:759–67.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lee MJ, et al. (1999) Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 99:301–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Youn SW, et al. (2011) COMP-Ang1 stimulates HIF-1α-mediated SDF-1 overexpression and recovers ischemic injury through BM-derived progenitor cell recruitment. Blood. 117:4376–86.CrossRefPubMedGoogle Scholar
  21. 21.
    Navaratna D, McGuire PG, Menicucci G, Das A. (2007) Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes. 56:2380–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Vestweber D, Winderlich M, Cagna G, Nottebaum AF. (2009) Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell. Biol. 19:8–15.CrossRefPubMedGoogle Scholar
  23. 23.
    Potter MD, Barbero S, Cheresh DA. (2005) Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state. J. Biol. Chem. 280:31906–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Young BA, et al. (2003) Protein tyrosine phosphatase activity regulates endothelial cell-cell interactions, the paracellular pathway, and capillary tube stability. Am. J. Physiol. Lung Cell Mol. Physiol. 285:L63–75.CrossRefPubMedGoogle Scholar
  25. 25.
    Weis S, et al. (2004) Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J. Clin. Invest. 113:885–94.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Allan LA, et al. (2003) Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat. Cell. Biol. 5:647–54.CrossRefPubMedGoogle Scholar
  27. 27.
    Dejana E. (2004) Endothelial cell-cell junctions: happy together. Nat. Rev. Mol. Cell. Biol. 5:261–70.CrossRefPubMedGoogle Scholar
  28. 28.
    Gavard J, Gutkind JS. (2006) VEGF controls endothelial-cell permeability by promoting the beta-arrestindependent endocytosis of VE-cadherin. Nat. Cell. Biol. 8:1223–34.CrossRefPubMedGoogle Scholar
  29. 29.
    Ukropec JA, Hollinger MK, Salva SM, Woolkalis MJ. (2000) SHP2 association with VE-cadherin complexes in human endothelial cells is regulated by thrombin. J. Biol. Chem. 275:5983–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Sui XF, et al. (2005) Receptor protein tyrosine phosphatase micro regulates the paracellular pathway in human lung microvascular endothelia. Am. J. Pathol. 166:1247–58.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Nawroth R, et al. (2002) VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO J. 21:4885–95.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Yaoita H, Ogawa K, Maehara K, Maruyama Y. (1998) Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation. 97:276–81.CrossRefPubMedGoogle Scholar
  33. 33.
    Hannigan GE, Coles JG, Dedhar S. (2007) Integrinlinked kinase at the heart of cardiac contractility, repair, and disease. Circ. Res. 100:1408–14.CrossRefPubMedGoogle Scholar
  34. 34.
    Lee SW, et al. (2009) Angiopoietin-1 protects endothelial cells from hypoxia-induced apoptosis via inhibition of PTEN. Korean Circ. J. 39:57–65.CrossRefGoogle Scholar
  35. 35.
    Song JQ, Teng X, Cai Y, Tang CS, Qi YF. (2009) Activation of Akt/GSK-3beta signaling pathway is involved in intermedin(1–53) protection against myocardial apoptosis induced by ischemia/reperfusion. Apoptosis. 14:1061–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Allan LA, Clarke PR. (2009) Apoptosis and autophagy: regulation of caspase-9 by phosphorylation. FEBS J. 276:6063–73.CrossRefPubMedGoogle Scholar
  37. 37.
    Kurokawa M, Kornbluth S. (2009) Caspases and kinases in a death grip. Cell. 138:838–54.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Losordo DW, et al. (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation. 98:2800–4.CrossRefPubMedGoogle Scholar
  39. 39.
    Schwarz ER, et al. (2000) Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation. J. Am. Coll. Cardiol. 35:1323–30.CrossRefPubMedGoogle Scholar
  40. 40.
    Asahara T, et al. (1998) Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res. 83:233–40.CrossRefPubMedGoogle Scholar
  41. 41.
    Sasaki H, Ray PS, Zhu L, Galang N, Maulik N. (2000) Oxidative stress due to hypoxia/reoxygenation induces angiogenic factor VEGF in adult rat myocardium: possible role of NFkappaB. Toxicology. 155:27–35.CrossRefPubMedGoogle Scholar
  42. 42.
    Lee KW, Lip GY, Blann AD. (2004) Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation. 110:2355–60.CrossRefPubMedGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011
www.feinsteininstitute.org

Authors and Affiliations

  • Sae-Won Lee
    • 1
  • Joo-Yun Won
    • 1
  • Hae-Young Lee
    • 1
  • Ho-Jae Lee
    • 1
  • Seock-Won Youn
    • 1
  • Ji-Young Lee
    • 1
  • Chung-Hyun Cho
    • 2
  • Hyun-Jai Cho
    • 1
  • Seil Oh
    • 1
  • In-Ho Chae
    • 1
  • Hyo-Soo Kim
    • 1
    • 3
  1. 1.Department of Internal Medicine, and Innovative Research Institute for Cell TherapySeoul National University HospitalSeoulKorea
  2. 2.Department of PhysiologyChoong-nam National UniversityDaejeonKorea
  3. 3.World Class University Program, Department of Molecular Medicine and Biopharmaceutical SciencesSeoul National UniversitySeoulKorea

Personalised recommendations